Abstract
To determine the efficacy and safety of intraperitoneal administration of darbepoetin in children with renal anemia on peritoneal dialysis, we conducted a single-arm, retrospective, two-centre study in which children were treated with intraperitoneal darbepoetin at the end of nightly intermittent peritoneal dialysis. Controls were those children treated with intraperitoneal erythropoietin six months before conversion to darbepoetin. Children were converted with the conversion factor 200 units erythropoietin = 1 μg darbepoetin. Children who started with darbepoetin, started with 0.45 μg/kg/week. Nineteen children entered the study. The mean age was 6.8 years. Eight children were converted from 201 U/kg/week intraperitoneal erythropoietin to 1.0 μg/kg/week intraperitoneal darbepoetin. They were treated for a median period of 31.5 months. Median darbepoetin dose for an adequate erythropoesis over this period was 0.79 μg/kg/week. All 19 children were treated with darbepoetin for a median period of 13.4 months. The median dose for an adequate erythropoesis over this period was 0.63 μg/kg/week. The peritonitis incidence during this study was once every 25.1 months. Three children developed hypertension; one child developed headache. These complications developed after a rapid increase of hemoglobin concentration. Intraperitoneal administration of darbepoetin is effective and safe for children on peritoneal dialysis.
Similar content being viewed by others
References
Egrie J, Grant JR, Gillies DK, Aoki KH, Strickland TW (1993) The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J 10:263
Egrie J, Browne J (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (suppl 3):3–13
Lerner G, Kale A, Warady B, Jabs K, Bunchman T, Heatherington A, Olson K, Messer-Mann L, Maroni B (2002) Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 17:933–937
Macdougall I (2001) An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 10 (suppl 3):14–21
Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T (2004) Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 19:1224–1230
Jadoel M, Vanrenterghem Y, Foret M, Walker R, Gray S (2004) Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19:898–903
Geary D, Keating L, Vigneux A, Stephens D, Hébert D, Harvey E (2005) Darbepoetin Alfa in children with chronic renal failure. Kidney Int 68:1759–1765
De Palo T, Giordano M, Palumbo F, Bellantuono R, Messina G, Colella V, Caringella A (2004) Clinical experience with darbepoietin alfa (NESP) in children undergoing dialysis. Pedriatr Nephrol 19:337–340
Rusthoven E, van de Kar N, Monnens L, Schröder C (2001) Long term effictiveness of intraperitoneal erythropoietin in children on NIPD by administration in small bags. Perit Dial Int 21:196–197
Reddingius R, Schröder C, Koster A, Monnens L (1994) Pharmacokinetics of recombinant human erytrhopoietin in children treated with continuous ambulatory peritoneal dialysis. Eur J Pediatr 153:850–854
Reddingius R, Schröder C, Monnens L (1992) Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis. Eur J Pediatr 151:540–542
National Kidney Foundation K/DOQI (2001) Clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 37(suppl 1):182–238
Van Damme-Lombaerts R, Broyer M, Businger J, Baldauf C, Stocker H (1994) A study of recombinant human erythropoietin in the treatment of anaemia of chronic renal failure in children on haemodialysis. Pediatr Nephrol 8:338–342
Scigalla P (1991) Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease. Contrib Nephrol 88:201–212
Troide L, Finkelstein F (2006) Treatment and outcome of CPD-associated peritonitis. Ann Clin Microbiol Antimicrob 6;5:6
Smith K, Bleyer A, Little W, Sane D (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538–548
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rijk, Y., Raaijmakers, R., van de Kar, N. et al. Intraperitoneal treatment with darbepoetin for children on peritoneal dialysis. Pediatr Nephrol 22, 436–440 (2007). https://doi.org/10.1007/s00467-006-0343-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-006-0343-8